Source comparison
CJC-1295 No DAC vs Other Peptides — Research Comparison
Research published in the Journal of Clinical Endocrinology & Metabolism found that modified GRF(1-29). The peptide sold as 'CJC-1295 No DAC'. Produces peak growth hormone elevation within 15 minutes of subcutaneous administration, returning to baseline by 90
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that modified GRF(1-29). The peptide sold as 'CJC-1295 No DAC'. Produces peak growth hormone elevation within 15 minutes of subcutaneous administration, returning to baseline by 90 minutes. Compare that to CJC-1295 with DAC, which maintains supraphysiologic GH levels for 144+ hours after a single injection. Same base structure. Opposite pharmacokinetics.
- Our team has worked with research institutions evaluating peptide protocols for years. The confusion around CJC-1295 No DAC isn't accidental. It's a naming problem that compounds into protocol design errors, dosing miscalculations, and wasted research time.
- How does CJC-1295 No DAC compare to other research peptides?
- CJC-1295 No DAC (modified GRF 1-29) mimics the pulsatile release pattern of endogenous GHRH with a plasma half-life of approximately 30 minutes, requiring multiple daily administrations for sustained effect. In contrast, CJC-1295 with DAC extends GH elevation across 6–8 days per dose through albumin binding, while GHRP-2 and GHRP-6 act on ghrelin receptors to amplify GH pulse amplitude without extending duration. The distinction reshapes dosing frequency, synergy protocols, and physiological mimicry in growth hormone research.
- The real comparison isn't just structural. It's operational. CJC-1295 No DAC was designed to replicate the body's natural growth hormone release rhythm. GHRP peptides were designed to amplify that rhythm's intensity. CJC-1295 with DAC was designed to override the rhythm entirely. Each serves a distinct research application, and substituting one for another based on cost or availability alone misses the point. This article covers how each peptide's mechanism translates into practical protocol design, what synergy means in GH research (and what it doesn't), and where modified GRF(1-29) outperforms alternatives. And where it doesn't.